Research Article
Bivalirudin vs. Heparin on Radial Artery Thrombosis during Transradial Coronary Intervention: An Optical Coherence Tomography Study
Table 1
Baseline characteristics of the study population.
| | | Unmatched cohort (n = 211) | Matched cohort (n = 119) | Std. mean diff. | | Bivalirudin (n = 67) | UFH (n = 144) | value | Bivalirudin (n = 47) | UFH (n = 75) | value | Before | After |
| | Propensity | 0.431 | 0.265 | | 0.376 | 0.375 | | 0.909 | 0.002 | | Age (years) | 60.4 ± 12.6 | 54.9 ± 11.9 | 0.003 | 58.9 ± 13.2 | 57.3 ± 11.0 | 0.445 | 0.432 | 0.040 | | Male gender | 51 (76.1%) | 125 (86.8%) | 0.052 | 44 (84.6%) | 66 (83.5%) | 0.870 | 0.249 | −0.090 | | Body mass index (kg/m2) | 25.6 (23.9–27.7) | 25.9 (23.6–28.4) | 0.996 | 25.4 (23.5–28.9) | 25.7 (23.8–29.0) | 0.873 | 0.010 | 0.021 | | Diabetes | 22 (32.8%) | 40 (27.8%) | 0.453 | 16 (30.8%) | 27 (34.2%) | 0.684 | 0.107 | −0.061 | | Hypertension | 45 (67.2%) | 70 (48.6%) | 0.012 | 33 (63.5%) | 49 (62.0%) | 0.868 | 0.392 | −0.081 | | Hyperlipidemia | 55 (82.1%) | 103 (71.5%) | 0.100 | 40 (76.9%) | 60 (75.9%) | 0.898 | 0.273 | −0.050 | | Current smoking | 39 (58.2%) | 98 (68.1%) | 0.163 | 34 (65.4%) | 52 (65.8%) | 0.959 | −0.198 | 0.116 | | PVD | 3 (4.5%) | 5 (3.5%) | 0.711 | 3 (5.8%) | 4 (5.1%) | 1.000 | 0.048 | 0.046 | | Family history | 12 (17.9%) | 18 (12.5%) | 0.295 | 8 (15.4%) | 14 (17.7%) | 0.726 | 0.140 | −0.075 | | Creatinine (μmol/L) | 75.00 (64.00–84.00) | 78.00 (66.25–89.75) | 0.130 | 75.00 (67.50–86.00) | 74.00 (63.00–88.00) | 0.510 | −0.240 | 0.090 | | Diagnoses | | | 0.065 | | | 0.702 | −0.433 | −0.112 | | MI | 65 (97.0%) | 129 (89.6%) | | 50 (96.2%) | 74 (93.7%) | | | | | UAP | 2 (3.0%) | 15 (10.4%) | | 2 (3.8%) | 5 (6.3%) | | | | | Multivessel disease, N (%) | 86.6% | 78.5% | | 82.7% | 82.3% | | | | | Antiplatelet medicine | | | | | | | | | | Aspirin | 67 (100%) | 144 (100%) | | 47 (100%) | 75 (100%) | | | | | Clopidogrel | 31 (46.3%) | 58 (40.3%) | | 23 (44.2%) | 30 (38.0%) | | | | | Ticagrelor | 36 (53.7%) | 86 (59.7%) | | 29 (55.8%) | 49 (62.0%) | | | | | Tirofiban | 24 (35.8%) | 31 (21.5%) | 0.028 | 17 (32.7%) | 16 (20.3%) | 0.109 | 0.296 | 0.159 | | Total dose of UFH (IU) | 8000 (7025, 9200) | | | 8000 (7200, 9000) | | | | | | Procedure type | | | 0.023 | | | 1.000 | 0.730 | 0.079 | | CAG | 1 (1.5%) | 15 (10.4%) | | 1 (1.9%) | 3 (3.8%) | | | | | PCI | 66 (98.5%) | 129 (89.6%) | | 51 (98.1%) | 76 (96.2%) | | | | | Procedure time (min) | 73.00 (61.00–87.00) | 72.00 (57.00–88.75) | 0.557 | 72.00 (61.25–81.50) | 69.00 (56.00–84.00) | 0.193 | 0.008 | 0.139 | | Number of total catheters | 2.07 ± 0.745 | 1.94 ± 0.936 | 0.132 | 1.97 ± 0.698 | 2.02 ± 1.019 | 0.899 | | | | Number of diagnostic catheters | 0.81 ± 0.625 | 0.79 ± 0.616 | 0.907 | 0.76 ± 0.582 | 0.83 ± 0.648 | 0.552 | | | | Number of guiding catheters | 1.26 ± 0.469 | 1.15 ± 0.557 | 0.022 | 1.22 ± 0.414 | 1.19 ± 0.627 | 0.271 | | |
|
|
PVD: peripheral vascular disease, MI: myocardial infarction, UAP: unstable angina pectoris, CAG: coronary angiography, and PCI: percutaneous coronary intervention.
|
